Last updated: February 25, 2026
What is NDC 62175-0485?
NDC 62175-0485 refers to a specific drug identified by the National Drug Code. Based on the NDC directory, this code corresponds to Remdesivir (Veklury), approved by the FDA for the treatment of COVID-19 in hospitalized patients. Its primary indication is severe COVID-19 cases requiring supplemental oxygen, mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).
Market Size and Demand Drivers
Global COVID-19 Treatment Market
The global COVID-19 therapeutics market has demonstrated significant volatility, but remains sizable due to ongoing pandemic management, emergence of variants, and vaccination efforts. The market size was estimated at approximately $12 billion in 2022, with projections to grow at a compound annual growth rate (CAGR) of around 4% through 2027 [1].
Remdesivir Market Share
Remdesivir captured a dominant position early in the pandemic, initially gaining rapid approval under Emergency Use Authorization (EUA) from the FDA in May 2020, then full approval in October 2020. By 2022, it accounted for roughly 50% of COVID-19 treatment sales in the U.S., with global sales reaching approximately $4.8 billion [2].
Key Demand Factors
- Regulatory approvals: Including FDA full approval and provisions by EMA and other health agencies.
- Pandemic evolution: Variants such as Omicron increased demand due to higher hospitalization rates.
- Guideline recommendations: Continued endorsement from WHO, CDC, and other health authorities.
- Vaccination rates: Lower vaccination coverage and vaccine efficacy against variants sustain demand for treatments like remdesivir.
Competitive Landscape
Major Products
-
Remdesivir (Veklury): The market leader in approved COVID-19 treatments.
-
Other therapeutics: Including molnupiravir (Lagevrio), Paxlovid (nirmatrelvir/ritonavir), and monoclonal antibodies.
Market Share Trends
Remdesivir holds approximately 60% of COVID-19 antiviral sales globally, followed by molnupiravir and Paxlovid, which gained higher market shares post-emergency authorizations in late 2021 and 2022 [3].
Price Analysis
Historical Pricing Data
-
United States (2022): The average wholesale price (AWP) for remdesivir was approximately $520 per vial.
-
Treatment course: A typical treatment involves six vials, totaling about $3,120 per patient.
Pricing Dynamics
- The U.S. government initially purchased remdesivir at around $520 per vial but has shifted towards direct sales to hospitals and payers, with negotiated prices generally ranging from $390 to $520 per vial.
- Commercial insurers and government programs have negotiated discounts, with some contracts as low as $250 per vial.
International Pricing
- Prices vary widely by country, influenced by regulatory policies, reimbursement systems, and negotiated discounts [4].
Future Price Projections
-
Short-term (next 2 years): Prices are expected to stay within the range of $250 to $520 per vial, depending on purchase volume and negotiated discounts.
-
Long-term (3-5 years): As demand stabilizes and COVID-19 treatment regimens evolve, prices could decline by 10–20% with increased competition from oral antivirals and possible generic entries in select markets [5].
Regulatory and Policy Impact
- Patent standing: Gilead Sciences holds the patent rights for remdesivir, with no current indications of patent expirations within the next five years.
- Pricing regulations: In some jurisdictions, governments are pushing for lower prices for pandemic-related drugs, which could influence future pricing strategies.
- Supply chain factors: Manufacturing capacity constraints and strategic stockpiling also impact market dynamics and pricing.
Market Outlook Summary
| Parameter |
Current Status |
Future Trends |
| Market Size (2022) |
$4.8 billion globally |
Stabilization post-pandemic growth, estimates ~$5.2B by 2025 |
| Price per vial (U.S.) |
$390 to $520 |
Potential decline to $250-$300 with increased competition |
| Market share |
Estimated 60% of COVID-19 antiviral sales |
Risk of decline as oral therapies gain market share |
| Regulatory landscape |
Full approval in multiple jurisdictions |
Expanded indications, potential price negotiations |
Key Takeaways
- The global remdesivir market remains sizable but faces headwinds from oral antiviral entrants and evolving treatment guidelines.
- Pricing exhibits downward pressure in the U.S. due to negotiated discounts and market competition.
- Long-term pricing stability depends on patent status, regulatory developments, and the role of oral and combination therapies.
- Overall, remdesivir's sales are expected to plateau or slightly grow within current margins, contingent on pandemic dynamics and policy changes.
FAQs
- What factors influence remdesivir's pricing strategies? Negotiated discounts with payers, manufacturing costs, competition from oral antivirals, and regulatory policies.
- Will remdesivir remain the dominant COVID-19 treatment? Its market share may diminish as oral treatments like Paxlovid and molnupiravir become more widely adopted.
- How does patent status affect future price projections? Patent protection limits generic competition, maintaining higher prices; expiration could lead to significant price reductions.
- Are there upcoming regulatory changes that could impact demand? Potential expansion of approved indications or new formulations could shape future demand.
- What is the long-term outlook for COVID-19 therapeutics? Sustained demand hinges on viral evolution, vaccine coverage, and therapeutic innovation.
References
- MarketsandMarkets. (2022). COVID-19 Therapeutics Market by Type, Indication, and Region.
- IQVIA. (2022). COVID-19 Treatment Market Data.
- GSK. (2022). Global COVID-19 Antiviral Approvals and Market Share.
- World Health Organization. (2022). Pricing of COVID-19 Therapeutics.
- EvaluatePharma. (2022). Long-term Drug Price Trends and Market Forecasts.
Note: Data is based on publicly available reports and estimates; actual prices and market sizes may vary with regional and contractual factors.
